GenMark Diagnostics, Inc. (GNMK)’s SVP – North American Com. Ops. Michael Gleeson Sold 437 Shares; 1 Bullish Analysts Covering Wipro Limited (WIT)

Among 11 analysts covering Wipro Limited (NYSE:WIT), 1 have Buy rating, 7 Sell and 3 Hold. Therefore 9% are positive. Wipro Limited had 13 analyst reports since August 5, 2015 according to SRatingsIntel. Bank of America maintained Wipro Limited (NYSE:WIT) rating on Friday, July 21. Bank of America has “Neutral” rating and $277 target. The firm has “Underperform” rating by Wedbush given on Friday, September 9. The firm has “Sell” rating by Credit Suisse given on Monday, January 22. Zacks upgraded Wipro Limited (NYSE:WIT) on Tuesday, September 22 to “Hold” rating. The rating was initiated by Sterne Agee CRT with “Underperform” on Thursday, December 17. The rating was downgraded by Nomura to “Reduce” on Monday, October 24. The firm earned “Equal-Weight” rating on Thursday, February 11 by Morgan Stanley. The stock has “Hold” rating by Zacks on Wednesday, August 5. CLSA downgraded Wipro Limited (NYSE:WIT) on Friday, July 7 to “Outperform” rating. The firm has “Underperform” rating by Jefferies given on Wednesday, June 7. See Wipro Limited (NYSE:WIT) latest ratings:

22/01/2018 Broker: Credit Suisse Rating: Sell Downgrade

Michael Gleeson, the SVP – North American Com. Ops. of Genmark Diagnostics Inc made transaction for 437 shares with an average market price per share of $5.1 in the company, that are with a grand total value of $2,242 US Dollars. Right now, Michael Gleeson owns 288,772 shares which are exactly 0.53% of Genmark Diagnostics Inc’s total market cap. This trade, which was filled on February 06, 2018 was revealed in a document with the Security Exchange Commission.

Analysts await GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report earnings on February, 27. They expect $-0.24 earnings per share, up 11.11% or $0.03 from last year’s $-0.27 per share. After $-0.28 actual earnings per share reported by GenMark Diagnostics, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

Investors sentiment decreased to 1.88 in Q3 2017. Its down 2.12, from 4 in 2017Q2. It dropped, as 11 investors sold GenMark Diagnostics, Inc. shares while 15 reduced holdings. 11 funds opened positions while 38 raised stakes. 56.57 million shares or 46.84% less from 106.41 million shares in 2017Q2 were reported. Alphaone Inv Serv Limited Liability Company accumulated 0.01% or 2,100 shares. Fdx Advsr accumulated 23,960 shares or 0.01% of the stock. Commercial Bank Of Montreal Can has 779 shares for 0% of their portfolio. Goldman Sachs Inc has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Ghost Tree Cap Ltd Liability Co stated it has 950,000 shares. Quantitative Systematic Strategies Lc has 17,621 shares. Moreover, State Board Of Administration Of Florida Retirement System has 0% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Savings Bank Of America De invested 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Blackrock invested in 3.39 million shares. Jpmorgan Chase & Co reported 4.40M shares. Glenmede Tru Na stated it has 1,000 shares or 0% of all its holdings. 460,677 were accumulated by Geode Limited Liability Com. Td Asset Management, Ontario – Canada-based fund reported 130,280 shares. California Public Employees Retirement Sys has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Rmb Cap Mgmt Limited Liability has 82,589 shares for 0.02% of their portfolio.

The stock increased 1.59% or $0.08 during the last trading session, reaching $5.1. About 308,128 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 116.11% since February 7, 2017 and is uptrending. It has outperformed by 99.41% the S&P500.

Since August 15, 2017, it had 0 insider buys, and 10 selling transactions for $587,604 activity. Stier Eric sold $17,086 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Monday, August 21. Mendel Scott sold $27,386 worth of stock or 2,898 shares. Williams Jennifer Anne sold 38,681 shares worth $351,223. Another trade for 1,933 shares valued at $18,267 was sold by Gleeson Michael. 1,277 shares were sold by Kayyem Jon Faiz, worth $12,068 on Monday, August 21. $78,539 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) was sold by MASSARANY HANY on Monday, August 21.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $279.46 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics has $1700 highest and $8 lowest target. $11.60’s average target is 127.45% above currents $5.1 stock price. Genmark Diagnostics had 19 analyst reports since October 14, 2015 according to SRatingsIntel. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Wednesday, August 30 by Needham. The stock has “Buy” rating by Canaccord Genuity on Monday, June 12. The firm has “Buy” rating by Canaccord Genuity given on Monday, October 30. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Wednesday, October 28 by Needham. On Monday, September 25 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock has “Buy” rating by Needham on Tuesday, January 24. The firm has “Market Perform” rating by Raymond James given on Friday, November 3. The rating was upgraded by Cowen & Co on Friday, September 16 to “Outperform”. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Friday, November 3 by Canaccord Genuity. As per Monday, August 7, the company rating was maintained by Canaccord Genuity.